82,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
41 °P sammeln
  • Gebundenes Buch

A substantial update of the previous edition, Screenwriting: The Sequence Approach deconstructs recent feature films and offers a new section analysing popular television series. A proven screenwriting method in emotionally engaging an audience, the sequence approach emphasises the underlying motives of each story plot to better convey its relation to the work as a whole. In this expanded second edition, Paul Gulino includes analyses of recent noteworthy films and serial dramas, such as Parasite, Barry and Breaking Bad, with an eye to how they manage audience attention, convey vital…mehr

Produktbeschreibung
A substantial update of the previous edition, Screenwriting: The Sequence Approach deconstructs recent feature films and offers a new section analysing popular television series. A proven screenwriting method in emotionally engaging an audience, the sequence approach emphasises the underlying motives of each story plot to better convey its relation to the work as a whole. In this expanded second edition, Paul Gulino includes analyses of recent noteworthy films and serial dramas, such as Parasite, Barry and Breaking Bad, with an eye to how they manage audience attention, convey vital information and deliver their emotional payloads. The aim of the book is to help writers move readily from the feature film to the serial form, mastering both. It is perfect for both beginning writers and those with experience in the feature screenplay form.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Paul Gulino is Associate Professor of Screenwriting at Chapman University, USA. He is an award-winning screenwriter, whose book, Screenwriting: The Sequence Approach (Bloomsbury, 2004) has been adopted as a textbook at schools and universities around the globe. He is also the co-author of The Science of Screenwriting: The Neuroscience Behind Storytelling Strategies (2018).